The effect of ischaemia/reperfusion injuries by pringle manoeuvre on the prognosis of hepatocellular carcinoma patients after radical excision

ISRCTN ISRCTN01960869
DOI https://doi.org/10.1186/ISRCTN01960869
ClinicalTrials.gov number NCT00725335
Secondary identifying numbers swhb001
Submission date
25/07/2008
Registration date
21/08/2008
Last edited
14/02/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Dong Jiahong
Scientific

Institute of Hepatobiliary Surgery
Chinese PLA General Hospital
Beijing
100000
China

Email xiaobinf@medmail.com.cn

Study information

Study designTreatment, parallel assignment, two-armed randomised, actively controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleThe effect of ischaemia/reperfusion injuries elicited by pringle manoeuvre on the prognosis of hepatocellular carcinoma patients after radical excision: a multicentre prospective randomised study
Study objectivesUntil now there are two popular procedures during the radical excision of primary liver cancer in China. One is to give a pringle manoeuvre to control the operative blood loss and the other is to use a combination of CUSA and TissueLink to control the bleeding in patients without liver ischaemia. According to recent experimental studies in rats, we know that ischaemia and reperfusion injury may contribute to the metastasis of the tumour, so we hypothesised that ischaemia and reperfusion injuries during the surgery may accelerate the outgrowth of liver cancer cells and affect the survival of the patients. In order to test the actual contribution of ischaemia on humans, we are conducting this prospective clinical trial to compare the two popular procedures' effect on the prognosis of liver cancer patients undergoing radical excision.

Please note that as of 08/09/2008 the actual start date of the trial is 09/09/2008. The previous anticipated start date of the trial was 15/08/2008.
Ethics approval(s)Ethics approval pending from the Ethics Committee of Southwest Hospital as of 28/07/2008.
Health condition(s) or problem(s) studiedHepatitis B virus related primary hepatocellular carcinoma
InterventionExperimental group: radical excision of liver cancer without liver ischaemia
Control group: radical excision of liver cancer under pringle manoeuvre

The total duration of follow-up for all treatment arms will be five years after the first radical excision operation.
Intervention typeOther
Primary outcome measure1. Disease free survival, measured 1, 3 and 5 years after the first radical excision operation
2. Total survival, measured 1, 3 and 5 years after the first radical excision operation
Secondary outcome measures1. Liver function test, measured at each follow-up timepoint, that is 1, 2, 4, 6, 8, 12, 16, 20, 24, 30, 36, 42, 48, 54 and 60 months after the first radical excision operation
2. Hospital stay, measured during peri-operation period
3. Intensive care unit stay, measured during peri-operation period
Overall study start date09/09/2008
Completion date01/12/2014

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants200
Key inclusion criteriaCurrent as of 11/09/2008:
The following changes have been made to the below two points of the inclusion criteria:
4. Hepatitis B surface antigens (HBsAg) positive
5. Tumour nodes in the liver can be radically excised

Initial inclusion criteria:
1. Aged from 18 to 65 years, without gender restriction
2. Clinical diagnosis of resectable primary liver cancer
3. The liver function tests showed: Child-Pugh grade A; clearance of indocyanine green at 15 minutes (CICG-R15) of 20%
4. Hepatitis B surface antigens (HBsAg) positive, hepatitis B deoxyribonucleic acid (HBV-DNA) less than 100,000 copies/ml
5. No more than two tumour nodes in the liver
6. No preoperative anti-cancer therapy
7. Written informed consent from the patient or legal guardian prior to entering the study
Key exclusion criteria1. Pregnancy
2. With extrahepatic tumour or lymph node metastasis
3. Tumour invasion or thrombosis in portal vein, hepatic vein or inferior vena cava
4. Surgical marginal positive
Date of first enrolment09/09/2008
Date of final enrolment01/12/2014

Locations

Countries of recruitment

  • China

Study participating centre

Institute of Hepatobiliary Surgery
Beijing
100000
China

Sponsor information

Institute of Hepatobiliary Surgery of PLA, Southwest Hospital (China)
University/education

c/o Feng Xiaobin
Third Military Medical University
30 Gaotanyan Street
Shapinba District
Chongqing
400038
China

ROR logo "ROR" https://ror.org/043sbvg03

Funders

Funder type

Hospital/treatment centre

Institute of Hepatobiliary Surgery of PLA, Southwest Hospital (China)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 03/08/2012 14/02/2019 Yes No

Editorial Notes

14/02/2019: Publication reference added.